The ceramide synthase family, often referred to as LASS (longevity assurance homologs), encompasses a group of enzymes crucial in sphingolipid metabolism. These enzymes are responsible for the synthesis of ceramides, a type of lipid molecule that plays a key role in cell membrane integrity and signaling pathways. Each ceramide synthase isoform (CerS1-6 in humans) prefers different fatty acyl-CoA substrates, leading to the production of ceramides with distinct acyl chain lengths. The ceramides synthesized by these enzymes are involved in various cellular processes, including apoptosis, cell proliferation, and stress response. Dysregulation of ceramide synthase activity is linked to numerous diseases, including cancer, neurodegenerative disorders, and metabolic conditions. Additionally, ceramides act as signaling molecules, influencing pathways like inflammation and cell survival, and are integral to the formation of lipid rafts in cell membranes.
Targeting ceramide synthase (LASS) for disruption or inhibition using small molecules is a strategic approach for understanding its biological functions and implications in diseases. By selectively inhibiting specific isoforms of ceramide synthase, researchers can elucidate the distinct roles of different ceramide species in cellular processes. Small molecule inhibitors allow for precise modulation of ceramide levels, facilitating studies on how changes in ceramide synthesis affect cellular signaling pathways. This approach is critical for dissecting the complex sphingolipid metabolism pathways and their impact on cell physiology. Inhibiting ceramide synthase can reveal insights into the mechanisms of diseases like cancer, where ceramide levels are often dysregulated.
VOIR ÉGALEMENT...
Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
---|---|---|---|---|---|---|
Fumonisin B1 | 116355-83-0 | sc-201395 sc-201395A | 1 mg 5 mg | $117.00 $469.00 | 18 | |
Un inhibiteur de la céramide synthase qui peut réduire l'activité de LASS4 en inhibant de manière compétitive la fonction de l'enzyme. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $199.00 $599.00 | 24 | |
Cet inhibiteur non compétitif de la sphingomyélinase neutre pourrait influencer les niveaux de céramides en régulant l'expression de LASS4. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Inhibiteur de la farnésyltransférase, pouvant affecter la modification post-traductionnelle des protéines qui régulent LASS4. | ||||||
Ceranib-2 | 1402830-75-4 | sc-507503 | 10 mg | $173.00 | ||
Inhibiteur spécifique de la céramide synthase qui peut diminuer l'activité de LASS4 par inhibition directe. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Inhibiteur de l'autophagie qui peut affecter le renouvellement des composants cellulaires, y compris LASS4. | ||||||
Desipramine hydrochloride | 58-28-6 | sc-200158 sc-200158A | 100 mg 1 g | $65.00 $115.00 | 6 | |
Inhibe la sphingomyélinase acide et pourrait entraîner une altération du métabolisme des sphingolipides, ce qui pourrait avoir un impact sur le LASS4. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $240.00 | 9 | |
Inhibe la phospholipase C spécifique de la phosphatidylcholine, affectant la dégradation de la sphingomyéline et, par extension, les niveaux de céramides qui peuvent influencer le LASS3. | ||||||
SKI II | 312636-16-1 | sc-204286 sc-204286A | 10 mg 50 mg | $94.00 $392.00 | 3 | |
Inhibe la sphingosine kinase, ce qui peut influencer les niveaux de sphingosine-1-phosphate et la synthèse de céramides, affectant potentiellement LASS3. | ||||||
4-Hydroxyphenylretinamide | 65646-68-6 | sc-200900 sc-200900A | 5 mg 25 mg | $104.00 $315.00 | ||
Induit la synthèse de céramides, influençant potentiellement l'activité de LASS3 par des mécanismes de rétroaction. | ||||||
Sphingomyelin | 85187-10-6 | sc-201381 sc-201381A | 100 mg 500 mg | $163.00 $520.00 | 3 | |
Bloque la céramide synthase, y compris LASS3, ce qui entraîne une diminution de la synthèse de céramide. |